Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 29710201.
- Also identified by DOI 10.1001/jamaoncol.2018.0275 and PMC identifier 6584319.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study evaluates the duration of response for crizotinib vs chemotherapy for patients with ALK-positive lung cancer using data from the PROFILE-1014 randomized clinical trial.
Medical subject headings
- Kaplan-Meier Estimate
- Neoplasms
- Progression-Free Survival
- Treatment Outcome